Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Chinese Patent Office
Queensland Health
Medtronic
McKinsey
Cerilliant
Deloitte
Cantor Fitzgerald
Johnson and Johnson
Chubb

Generated: January 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202788

« Back to Dashboard

NDA 202788 describes SUBSYS, which is a drug marketed by Insys Dev Co Inc and is included in one NDA. It is available from one supplier. There are eight patents protecting this drug and one Paragraph IV challenge. Additional details are available on the SUBSYS profile page.

The generic ingredient in SUBSYS is fentanyl. There are thirty-one drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the fentanyl profile page.
Summary for 202788
Tradename:SUBSYS
Applicant:Insys Dev Co Inc
Ingredient:fentanyl
Patents:8
Therapeutic Class:Analgesics
Formulation / Manufacturing:see details
Pharmacology for NDA: 202788
Mechanism of ActionFull Opioid Agonists
Medical Subject Heading (MeSH) Categories for 202788
Suppliers and Packaging for NDA: 202788
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SUBSYS fentanyl SPRAY;SUBLINGUAL 202788 NDA Insys Therapeutics, Inc. 20482-001 20482-001-30 30 BLISTER PACK in 1 CARTON (20482-001-30) > 1 BOTTLE, SPRAY in 1 BLISTER PACK > 1 SPRAY in 1 BOTTLE, SPRAY
SUBSYS fentanyl SPRAY;SUBLINGUAL 202788 NDA Insys Therapeutics, Inc. 20482-001 20482-001-10 10 BLISTER PACK in 1 CARTON (20482-001-10) > 1 BOTTLE, SPRAY in 1 BLISTER PACK > 1 SPRAY in 1 BOTTLE, SPRAY

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SPRAY;SUBLINGUALStrength0.1MG
Approval Date:Jan 4, 2012TE:RLD:Yes
Patent:➤ SubscribePatent Expiration:Apr 27, 2030Product Flag?YSubstance Flag?Delist Request?
Patent:➤ SubscribePatent Expiration:Apr 27, 2030Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF PAIN
Patent:➤ SubscribePatent Expiration:Jan 25, 2027Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Healthtrust
Federal Trade Commission
Colorcon
Teva
Harvard Business School
Julphar
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot